Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.880
-0.020 (-1.05%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Company Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.

The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.

Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals logo
Country United States
Founded 2017
IPO Date Jun 25, 2021
Industry Biotechnology
Sector Healthcare
Employees 4
CEO David Luci

Contact Details

Address:
259 Liberty Avenue
Staten Island, New York 10305
United States
Phone 917 533 1469
Website acurxpharma.com

Stock Details

Ticker Symbol ACXP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0001736243
CUSIP Number 00510M104
ISIN Number US00510M1045
SIC Code 2834

Key Executives

Name Position
David P. Luci CPA, Esq., J.D. Co-Founder, President, Chief Executive Officer, Corporate Secretary and Director
Robert J. DeLuccia Co-Founder and Executive Chairman
Robert G. Shawah CPA, CPA Co-Founder and Chief Financial Officer

Latest SEC Filings

Date Type Title
Aug 9, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Jun 17, 2024 8-K Current Report
May 15, 2024 8-K Current Report
May 14, 2024 10-Q Quarterly Report
Apr 29, 2024 ARS Filing
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Apr 17, 2024 RW Filing
Apr 2, 2024 FWP Free Writing Prospectus